Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Multidisciplinary Management of Isocitrate Dehydrogenase-Mutated Gliomas in a Contemporary Molecularly Defined Era.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 20 Jul 2024

Kotecha Rupesh, Schiff David, Chakravarti Arnab, Fleming Jessica L, Brown Paul D, Puduvalli Vinay K, Vogelbaum Michael A, Gondi Vinai, Gallus Marco, Okada Hideho, Mehta Minesh P

Abstract excerpt

Mutations in isocitrate dehydrogenase (IDH) genes, an early step in the ontogeny of lower-grade gliomas, induce global epigenetic changes characterized by a hypermethylation phenotype and are critical to tumor classification, treatment decision making, and estimation of patient prognosis. The introduction of IDH inhibitors to block the oncogenic neomorphic function of the mutated protein has resulted in new...

Topics

Join the communities discussing this publication.

Brain Neoplasms
Glioma
Glioma Diagnosis and Treatment
Histone Deacetylase Inhibitors Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Isocitrate Dehydrogenase

Pancreatic and Hepatic Oncology Research

Source

Open in PubMed Open full text

Identifiers

PMID: 38833641
DOI: 10.1200/JCO.23.02195
PMCID: PMC11283772

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Multidisciplinary Management of Isocitrate Dehydrogenase-Mutated Gliomas in a Contemporary Molecularly Defined Era.PMID 38833641Read ↗

Therapies for IDH-Mutant Gliomas.Semantic proximity Read ↗

The biological significance of tumor grade, age, enhancement, and extent of resection in IDH-mutant gliomas: How should they inform treatment decisions in the era of IDH inhibitors?Semantic proximity Read ↗

Precision Oncology in Lower-Grade Gliomas: Promises and Pitfalls of Therapeutic Strategies Targeting IDH-MutationsSemantic proximity Read ↗

Recent developments and future directions in adult lower-grade gliomas: Society for Neuro-Oncology (SNO) and European Association of Neuro-Oncology (EANO) consensusSemantic proximity Read ↗

IDH Inhibitors and Beyond: The Cornerstone of Targeted Glioma Treatment.Semantic proximity Read ↗

Targeting IDH1/IDH2 mutations in gliomas.Semantic proximity Read ↗

Treatment Options for IDH-Mutant Malignant Gliomas.Semantic proximity Read ↗

Management of Adult Patients With Isocitrate Dehydrogenase-Mutant Gliomas in Australia: An Expert Position Statement From the Cooperative Trials Group for Neuro-Oncology.Semantic proximity Read ↗

Bridging Cancer Biology with the Clinic: Comprehending and Exploiting IDH Gene Mutations in Gliomas.Semantic proximity Read ↗

State of the Art in Low-Grade Glioma Management: Insights From Isocitrate Dehydrogenase and Beyond.Semantic proximity Read ↗

Isocitrate dehydrogenase mutations in defining the biology of and supporting clinical decision making in glioblastoma.Semantic proximity Read ↗

Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.